当前位置: X-MOL 学术Cancer Discov. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Precision Targeting of Mutant PI3Kα
Cancer Discovery ( IF 28.2 ) Pub Date : 2024-02-08 , DOI: 10.1158/2159-8290.cd-23-1392
Grace Q. Gong 1, 2 , Bart Vanhaesebroeck 1
Affiliation  

Summary: PIK3CA, which encodes the p110α catalytic subunit of PI 3-kinase alpha (PI3Kα), is one of the most frequently genetically activated kinases in solid tumors. In two back-to-back papers, Varkaris and colleagues report on the development of a novel allosteric PI3Kα-mutant–selective inhibitor and early clinical experience with this compound. See related article by Varkaris et al., p. 227 (6) . See related article by Varkaris et al., p. 240 (5) .

中文翻译:

突变 PI3Kα 的精确靶向

摘要:PIK3CA 编码 PI 3 激酶 α (PI3Kα) 的 p110α 催化亚基,是实体瘤中最常见的基因激活激酶之一。在两篇连续的论文中,Varkaris 及其同事报告了一种新型变构 PI3Kα 突变选择性抑制剂的开发以及该化合物的早期临床经验。请参阅 Varkaris 等人的相关文章,第 17 页。 227(6)。请参阅 Varkaris 等人的相关文章,第 17 页。 240(5)。
更新日期:2024-02-08
down
wechat
bug